Edit |   |
---|---|
Antigenic Specificity | MAPT (Gosuranemab biosimilar) |
Clone | monoclonal |
Host Species | Chimeric Human/Mouse |
Reactive Species | human |
Isotype | IgG4 kappa |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Gosuranemab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MAPT, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Gosuranemab (BIIB092) is a humanized IgG4 monoclonal anti-antibody targeting the N-terminal tau protein (eTau). The basic principle of this treatment method is based on the hypothesis that eTau is involved in the spread of pathological diseases. |
Immunogen | n/a |
Other Names | Gosuranemab, MAPT, 1788032-39-2 |
Gene, Accession # | CAS: 1788032-39-2 |
Catalog # | abx831488 |
Price | please inquire |
Order / More Info | MAPT (Gosuranemab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950